To further examine the predictive efficacy of risk score for immunotherapy response, the clinical information and transcriptome data of HCC patients treated with immunotherapy were analyzed using the GSE135222 (anti-PD1 therapy), GSE78220 (anti-PD1 therapy), and GSE91061 (anti-CTLA4 and anti-PD1 therapy) datasets. Here, CTLA4 is linked to hepatocellular carcinoma.